Adragos Pharma acquires Sanofi’s sterile fill-finish facility in France

The Maisons-Alfort site adds high-volume, pre-filled syringe manufacturing to the German CDMO’s existing sterile injectables network in Europe.

April 2, 2026

Adragos Pharma, a Munich, Germany-based contract development and manufacturing organization (CDMO), has completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France from Sanofi. Financial terms of the transaction were not disclosed.

The Maisons-Alfort site, located in the southeastern suburbs of Paris, is designed for industrial-scale manufacturing of pre-filled syringes, liquid vials, and lyophilized vials, according to the announcement. The facility has been regularly audited by international health authorities including France’s ANSM, China’s NMPA, South Korea’s MFDS, and Brazil’s ANVISA, the company said.

The acquisition expands Adragos’ sterile injectables network, adding pre-filled syringe manufacturing capabilities to its existing vial and ampoule filling operations in Jura, Switzerland, and Livron, France, according to the company. Employees from the Maisons-Alfort site are joining Adragos as part of the transaction.

Andreas Raabe, CEO of Adragos Pharma, said in a statement the company intends to invest in and further develop the site into a fill-finish platform, describing the acquisition as aligned with its strategy to expand sterile manufacturing capacity in Europe.

This piece was created with the help of generative AI tools and edited by our content team for clarity and accuracy.